Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8X94

Structure of human TRPV1 in complex with antagonist --protein purified without CHS

Summary for 8X94
Entry DOI10.2210/pdb8x94/pdb
EMDB information38161
DescriptorTransient receptor potential cation channel subfamily V member 1,Green fluorescent protein, 4-(7-Hydroxy-2-isopropyl-4-oxoquinazolin-3(4H)-yl)benzonitrile, CHOLESTEROL (3 entities in total)
Functional Keywordschannel, membrane protein
Biological sourceHomo sapiens (human)
More
Total number of polymer chains4
Total formula weight503958.88
Authors
Fan, J.,Lei, X. (deposition date: 2023-11-29, release date: 2024-08-14, Last modification date: 2024-08-21)
Primary citationFan, J.,Ke, H.,Lei, J.,Wang, J.,Tominaga, M.,Lei, X.
Structural basis of TRPV1 inhibition by SAF312 and cholesterol.
Nat Commun, 15:6689-6689, 2024
Cited by
PubMed Abstract: Transient Receptor Potential Vanilloid 1 (TRPV1) plays a central role in pain sensation and is thus an attractive pharmacological drug target. SAF312 is a potent, selective, and non-competitive antagonist of TRPV1 and shows promising potential in treating ocular surface pain. However, the precise mechanism by which SAF312 inhibits TRPV1 remains poorly understood. Here, we present the cryo-EM structure of human TRPV1 in complex with SAF312, elucidating the structural foundation of its antagonistic effects on TRPV1. SAF312 binds to the vanilloid binding pocket, preventing conformational changes in S4 and S5 helices, which are essential for channel gating. Unexpectedly, a putative cholesterol was found to contribute to SAF312's inhibition. Complemented by mutagenesis experiments and molecular dynamics simulations, our research offers substantial mechanistic insights into the regulation of TRPV1 by SAF312, highlighting the interplay between the antagonist and cholesterol in modulating TRPV1 function. This work not only expands our understanding of TRPV1 inhibition by SAF312 but also lays the groundwork for further developments in the design and optimization of TRPV1-related therapies.
PubMed: 39107321
DOI: 10.1038/s41467-024-51085-3
PDB entries with the same primary citation
Experimental method
ELECTRON MICROSCOPY (2.55 Å)
Structure validation

237423

PDB entries from 2025-06-11

PDB statisticsPDBj update infoContact PDBjnumon